TMCnet News
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingWALTHAM, Mass. and BOULDER, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its upcoming posters for bezuclastinib at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Washington, D.C. from February 23-26, 2024. The company will host a virtual investor webcast on Friday, February 23 at 8:00 a.m. ET. Poster Details Poster Presentation Title: Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) Poster Presentation Title: Physician and Patient Perspectives on Relevant and Burdensome Symptoms of Non-Advanced Systemic Mastocytosis Investor Webcast Information A webcast on Friday, February 23 at 8:00 a.m. ET to discuss the SUMMIT Part 1b data will be led by Andrew Robbins, Cogent’s President and Chief Executive Officer, and will include a presentation by PD Dr. Frank Siebenhaar, M.D., Head University Outpatient Clinic, Institute of Allergology, Charité - Universitätsmedizin Berlin. The event will be accessible on the Investors and Media page of Cogent’s website at investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Cogent Biosciences, Inc. Contact: |